Fetal risks of maternal pharmacotherapy: Identifying signals

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

14 Scopus citations

Abstract

Pregnant women may be exposed to a variety of medications that may exert toxic or teratogenic effects on the fetus. Since the thalidomide disaster, physicians and pregnant women tend to withhold medications during pregnancy, although the risk of teratogenic effect from most drugs in therapeutic doses is nonexistent. This chapter will review the principles of teratology and the pharmacoepidemiological evidence for drug safety/risk in human gestation.

Original languageEnglish
Title of host publicationPediatric Clinical Pharmacology
EditorsHannsjorg Seyberth, Hannsjorg Seyberth, Matthias Schwab, Matthias Schwab, Anders Rane
Pages285-294
Number of pages10
DOIs
StatePublished - 2011
Externally publishedYes

Publication series

NameHandbook of Experimental Pharmacology
Volume205
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Keywords

  • Bias
  • Drugs
  • Fetal safety
  • Fetus
  • Teratogenicity
  • Teratology

Fingerprint

Dive into the research topics of 'Fetal risks of maternal pharmacotherapy: Identifying signals'. Together they form a unique fingerprint.

Cite this